The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 27, 2012
Filed:
Jul. 06, 2009
Karl Salzwedel, Olney, MD (US);
Feng LI, Brookings, SD (US);
Carl T. Wild, Gaithersburg, MD (US);
Graham P. Allaway, Darnestown, MD (US);
Eric O. Freed, Frederick, MD (US);
Karl Salzwedel, Olney, MD (US);
Feng Li, Brookings, SD (US);
Carl T. Wild, Gaithersburg, MD (US);
Graham P. Allaway, Darnestown, MD (US);
Eric O. Freed, Frederick, MD (US);
The United States of America, as represented by the Secretary, Department & Human Services, Washington, DC (US);
Myrexis, Inc., Salt Lake City, UT (US);
Abstract
Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.